ONE TEST FOR CANCER - 20/20 GENESYSTEM INC.

Rockville,  MD 
United States
https://onetestforcancer.com/
  • Booth: 9527

Multi-Cancer Blood Test:  OneTEST is 20/20’s multi-cancer test to screen for multiple cancer types from one blood sample.  Importantly 20/20’s algorithms and analytics substantially improve the accuracy of panels of cancer tumor marker tests currently used by physicians worldwide — without requiring new equipment or change in current practice.

Brands: One Test For Cancer 20/20 GeneSystems Paula's Test Cancer Screening BIOCHECK POWDER SCREENING TEST KIT


 Products

  • One Test For Cancer
    OneTEST is 20/20’s multi-cancer test screening for multiple cancer types from one blood sample. Importantly 20/20’s algorithms and analytics substantially improve the accuracy of panels of cancer tumor marker tests currently used by physicians worldwide....

  • Multi-Cancer Blood Test:  OneTest™  is 20/20’s multi-cancer test to screen for multiple cancer types from one blood sample.  Importantly 20/20’s algorithms and analytics substantially improve the accuracy of panels of cancer tumor marker tests currently used by physicians worldwide — without requiring new equipment or change in current practice.

    Overview

    Cancer Among U.S. Firefighters—Findings of U.S. Government Study • Limitations of current recommended screening approaches for firefighters

    Our OneTest™ Solution

    • Product Overview
    • OneTest™  Biomarkers & High Incidence Cancers in Firefighters
    • The Added Benefit of the OneTest™  Algorithms
    • The Power of Machine Learning & Yearly Testing
    • Special Algorithm for Fire Exposure o 20/20’s History with and Commitment to the Fire Service

    Cancer Among U.S. Firefighters

    5-year study of ~30,000 U.S. fire fighters by NIOSH ending in 2015 found that

    • Firefighters proportionately had a greater number of cancer diagnoses and cancer-related deaths than the general U.S. population.
    • Mostly digestive, oral, respiratory, and urinary cancers.
    • More cases of certain cancers among younger fire fighters (e.g. bladder & prostate)
    • The chance of lung cancer diagnosis or death increased with amount of time spent at fires.

    See https://www.cdc.gov/niosh/pgms/worknotify/pdfs/ff-cancer-factsheetfinal.pdf

    Limitations of Recommended Cancer Screening Guidelines for Firefighters

    About 97% of firefighters are men (NFPA)

    The recommended cancer screening guidelines (for men) of the U.S. Preventative Services Task Force, American Cancer Society, and other leading medical groups fail to adequately address many cancers which firefighters are shown to be at increased risk at younger ages: o Lung (especially mesothelioma)

    • Stomach
    • Esophagus
    • Intestines
    • Kidney
    • others

    Introduction to OneTest™

    Blood test (venipuncture) for early detection of multiple cancers (lung, liver, esophagus, pancreatic, stomach, prostate, + others)

    • Measures panel of 6 biomarkers (tumor antigens) and captures clinical factors; uses machine learning
    • Intended for healthy (asymptomatic) population
    • Consumer self-pay: ~$189 for general public; $99 for firefighters (8% of on-line orders from firefighters)
    • Based on testing paradigm very popular in East Asian “Health Check Centers”
    • Developed by 20/20 GeneSystems, Inc., Rockville, MD www.2020gene.com the developer of the BioCheck® suspicious powder screening kits, popular with hundreds of fire departments worldwide

    Foundations of OneTest™

    • Tens of thousands of "Health Check Centers", mostly in East Asia (Japan, Korea, China, Taiwan) as well as in Europe test panels tumor antigens on tens of millions of healthy individuals each year
    • These tests are overwhelmingly self-pay (or employer paid); not covered by national insurance programs
    • Approach proven effective in detecting early stage cancer based on large scale real-world evidence study from largest hospital in Taiwan published in 2015

    Core Elements

    Tumor biomarkers tested:

    • Male: AFP, CEA, CA19-9, CYFRA21-1, CA-125, PSA
    • Female: AFP, CEA, CA19-9, CYFRA21-1, CA125, CA15-3
    • Utilize FDA approved immunoassay analyzers (Roche Diagnostics) and detection kits
    • Include machine learning algorithms powered by data from tens of thousands of asymptomatic individuals ("Gold standard") wherein cancers were diagnosed w/ in one year after biomarker tests tested.
    • Collect and integrate into algorithms clinical factors that potentially contribute to false -/+
    • One-year outcome data continually collected from users for ongoing accuracy improvement and machine learning.

    Algorithm improvements over Standard Biomarker Testing

    Compares patterns of biomarkers and clinical factors to reference set of over 25,000 individuals (asymptomatic) previously screened with same biomarker set for whom one year cancer outcomes are known.

    • Demonstrated to help (i) detect some cancers that may be otherwise missed with biomarker measurements alone and (ii) reduce false positives and alarm
    • Studies show algorithm helps detect 2x more cancers in males 4x more cancers in females than biomarker levels alone
    • Continued year-over-year sensitivity improvements anticipated due to (i) growth of database, and (ii) value of serial tracking.

    Ongoing Machine Learning

    • Seek to screen 20,000+ American firefighters yearly by 2021 (2% of firefighters)
    • To collect expanded health + fire fighting history
    • Residual serum specimens to be used for research into novel biomarkers (e.g. cell-free DNA)

    The Detection Sensitivity Improves with Yearly (Serial) Testing

    In a study in the United Kingdom, CEA levels increased towards diagnosis in a significant proportion (1/3) of colorectal cancer (CRC) cases (half of late-stage cases), whereas longitudinal profiles were static in both benign and non-cancer controls. Combining CEA with other biomarkers (e.g. CA-19.9) further improves detection capabilities for CRC according to various studies. Other published studies support the value of yearly (serial) testing with OneTest™  biomarkers in pancreatic, ovarian, and liver cancers.

    Our Longstanding Commitment to the Fire Service

    • 20/20 Founder and CEO is a former volunteer firefighter
    • Hundreds of Fire Departments use our very popular BioCheck® kits for screening suspicious powders (see www.BioCheckInfo.com)
    • Offering generous product discount of $99 for firefighters (limited time only)

    For More Information Visit www.OneTestforCancer.com

  • One Test For Cancer
    OneTEST is 20/20’s multi-cancer test screening for multiple cancer types from one blood sample. Importantly 20/20’s algorithms and analytics substantially improve the accuracy of panels of cancer tumor marker tests currently used by physicians worldwide....

  • Multi-Cancer Blood Test:  OneTest™  is 20/20’s multi-cancer test to screen for multiple cancer types from one blood sample.  Importantly 20/20’s algorithms and analytics substantially improve the accuracy of panels of cancer tumor marker tests currently used by physicians worldwide — without requiring new equipment or change in current practice.

    Overview

    Cancer Among U.S. Firefighters—Findings of U.S. Government Study • Limitations of current recommended screening approaches for firefighters

    Our OneTest™ Solution

    • Product Overview
    • OneTest™  Biomarkers & High Incidence Cancers in Firefighters
    • The Added Benefit of the OneTest™  Algorithms
    • The Power of Machine Learning & Yearly Testing
    • Special Algorithm for Fire Exposure o 20/20’s History with and Commitment to the Fire Service

    Cancer Among U.S. Firefighters

    5-year study of ~30,000 U.S. fire fighters by NIOSH ending in 2015 found that

    • Firefighters proportionately had a greater number of cancer diagnoses and cancer-related deaths than the general U.S. population.
    • Mostly digestive, oral, respiratory, and urinary cancers.
    • More cases of certain cancers among younger fire fighters (e.g. bladder & prostate)
    • The chance of lung cancer diagnosis or death increased with amount of time spent at fires.

    See https://www.cdc.gov/niosh/pgms/worknotify/pdfs/ff-cancer-factsheetfinal.pdf

    Limitations of Recommended Cancer Screening Guidelines for Firefighters

    About 97% of firefighters are men (NFPA)

    The recommended cancer screening guidelines (for men) of the U.S. Preventative Services Task Force, American Cancer Society, and other leading medical groups fail to adequately address many cancers which firefighters are shown to be at increased risk at younger ages: o Lung (especially mesothelioma)

    • Stomach
    • Esophagus
    • Intestines
    • Kidney
    • others

    Introduction to OneTest™

    Blood test (venipuncture) for early detection of multiple cancers (lung, liver, esophagus, pancreatic, stomach, prostate, + others)

    • Measures panel of 6 biomarkers (tumor antigens) and captures clinical factors; uses machine learning
    • Intended for healthy (asymptomatic) population
    • Consumer self-pay: ~$189 for general public; $99 for firefighters (8% of on-line orders from firefighters)
    • Based on testing paradigm very popular in East Asian “Health Check Centers”
    • Developed by 20/20 GeneSystems, Inc., Rockville, MD www.2020gene.com the developer of the BioCheck® suspicious powder screening kits, popular with hundreds of fire departments worldwide

    Foundations of OneTest™

    • Tens of thousands of "Health Check Centers", mostly in East Asia (Japan, Korea, China, Taiwan) as well as in Europe test panels tumor antigens on tens of millions of healthy individuals each year
    • These tests are overwhelmingly self-pay (or employer paid); not covered by national insurance programs
    • Approach proven effective in detecting early stage cancer based on large scale real-world evidence study from largest hospital in Taiwan published in 2015

    Core Elements

    Tumor biomarkers tested:

    • Male: AFP, CEA, CA19-9, CYFRA21-1, CA-125, PSA
    • Female: AFP, CEA, CA19-9, CYFRA21-1, CA125, CA15-3
    • Utilize FDA approved immunoassay analyzers (Roche Diagnostics) and detection kits
    • Include machine learning algorithms powered by data from tens of thousands of asymptomatic individuals ("Gold standard") wherein cancers were diagnosed w/ in one year after biomarker tests tested.
    • Collect and integrate into algorithms clinical factors that potentially contribute to false -/+
    • One-year outcome data continually collected from users for ongoing accuracy improvement and machine learning.

    Algorithm improvements over Standard Biomarker Testing

    Compares patterns of biomarkers and clinical factors to reference set of over 25,000 individuals (asymptomatic) previously screened with same biomarker set for whom one year cancer outcomes are known.

    • Demonstrated to help (i) detect some cancers that may be otherwise missed with biomarker measurements alone and (ii) reduce false positives and alarm
    • Studies show algorithm helps detect 2x more cancers in males 4x more cancers in females than biomarker levels alone
    • Continued year-over-year sensitivity improvements anticipated due to (i) growth of database, and (ii) value of serial tracking.

    Ongoing Machine Learning

    • Seek to screen 20,000+ American firefighters yearly by 2021 (2% of firefighters)
    • To collect expanded health + fire fighting history
    • Residual serum specimens to be used for research into novel biomarkers (e.g. cell-free DNA)

    The Detection Sensitivity Improves with Yearly (Serial) Testing

    In a study in the United Kingdom, CEA levels increased towards diagnosis in a significant proportion (1/3) of colorectal cancer (CRC) cases (half of late-stage cases), whereas longitudinal profiles were static in both benign and non-cancer controls. Combining CEA with other biomarkers (e.g. CA-19.9) further improves detection capabilities for CRC according to various studies. Other published studies support the value of yearly (serial) testing with OneTest™  biomarkers in pancreatic, ovarian, and liver cancers.

    Our Longstanding Commitment to the Fire Service

    • 20/20 Founder and CEO is a former volunteer firefighter
    • Hundreds of Fire Departments use our very popular BioCheck® kits for screening suspicious powders (see www.BioCheckInfo.com)
    • Offering generous product discount of $99 for firefighters (limited time only)

    For More Information Visit www.OneTestforCancer.com


Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".


For Technical Support with this webpage, please contact support.